Abbott Laboratories enters 2026 strategically focused on metabolic health and consumer-facing biowearables, exemplified by its Lingo platform and planned participation at CES 2026 beginning January 6. The company has successfully pivoted from high-volume COVID-19 testing, strengthening its position as a defensive growth stock through diversified medical devices and diagnostics. Despite ongoing NEC litigation and a late-2025 Libre 3 manufacturing correction, analysts generally hold a 'Moderate Buy' consensus with a 12-month average price target of $146.61. However, Zacks assigned a short-term 'Sell' rating. The stock recorded a modest +0.25% after-hours gain on January 1, 2026, closing at $125.60.